Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
A quarter of people taking antiretroviral therapy in Kenya have exhausted current treatment options

Affordable third-line antiretrovirals are urgently needed in resource-limited settings, according to research conducted in Kenya and published in the online edition of AIDS. The study showed that

Published
25 April 2017
By
Michael Carter
Switching from Atripla to generic-containing regimens can produce large cost savings

Switching from branded Atripla to regimens that include at least one generic drug formulation can achieve big cost savings without compromising virological efficacy, according to research from Brighton presented

Published
23 April 2017
By
Michael Carter
Bone density improves in people who switch from tenofovir DF to tenofovir alafenamide

After three years, tenofovir alafenamide (TAF) for first-line HIV treatment was better at suppressing viral load and safer for the bones and kidneys than the older tenofovir

Published
27 March 2017
By
Liz Highleyman
Dolutegravir monotherapy fails to maintain HIV viral suppression, but dolutegravir + lamivudine looks good

Dolutegravir used alone without other antiretrovirals was unable to keep viral load suppressed in some people who switched from a standard three-drug combination regimen, according to research

Published
09 March 2017
By
Liz Highleyman
Dual antiretroviral regimen maintains durable HIV suppression after switch

People who switched from standard antiretroviral therapy (ART) to a two-drug regimen of dolutegravir (Tivicay) plus rilpivirine (Edurant) were able to maintain an undetectable viral load

Published
15 February 2017
By
Liz Highleyman
GlaxoSmithKline’s New Drug Challenges HIV Treatment Orthodoxy

GlaxoSmithKline PLC’s ViiV Healthcare announced positive phase-three trial results for its new HIV drug in a dual-drug regimen, supporting the company’s audacious bet that it can shift the treatment orthodoxy away from three-drug combinations.

Published
20 December 2016
From
Wall Street Journal
High prevalence of resistance to zidovudine among people in sub-Saharan Africa experiencing virological failure with tenofovir-containing ART

A significant proportion of people with virological failure after treatment with tenofovir-containing antiretroviral therapy (ART) have resistance to thymidine analogues (stavudine and zidovudine), and in many cases other

Published
15 December 2016
By
Michael Carter
Tenofovir alafenamide works well and improves kidney and bone markers in older people living with HIV

A co-formulation of tenofovir alafenamide (TAF) plus emtricitabine, used with a third antiretroviral drug, maintained viral suppression as well as tenofovir disoproxil fumarate (TDF) plus emtricitabine in older

Published
10 November 2016
By
Liz Highleyman
Darunavir/ritonavir & lamivudine matches triple-drug therapy

Simplifying antiretroviral therapy to a two-drug combination of lamivudine plus the protease inhibitor darunavir (Prezista) boosted by ritonavir is just as effective as a three-drug regimen in

Published
31 October 2016
By
Keith Alcorn
Two-drug HIV therapy just as effective as three-drug therapy

Simplification of an antiretroviral treatment to a boosted protease inhibitor and the nucleoside analogue lamivudine (a dual regimen) is highly effective in people switching from a stable three-drug

Published
25 October 2016
By
Keith Alcorn
← First12345...27Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.